An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A

Trial Profile

An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Efmoroctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Registrational
  • Acronyms ASPIRE
  • Sponsors Biogen; Bioverativ
  • Most Recent Events

    • 07 Dec 2017 This trial has been completed in Belgium (End Date: 2017-10-18) according to (European Clinical Trials Database record; EudraCT2011-003072-37).
    • 20 Nov 2017 This trial has been completed in Sweden (End Date: 2017-10-18)
    • 01 Nov 2017 According to a Bioverativ media release, longitudinal analysis from the study will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top